S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
US Dollar Replaced By "Biden Bucks"? (Ad)
OTCMKTS:FSNUY

Fresenius SE & Co. KGaA - FSNUY Stock Forecast, Price & News

$6.35
-0.04 (-0.63%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.25
$6.37
50-Day Range
$6.19
$8.35
52-Week Range
$6.09
$14.20
Volume
168,839 shs
Average Volume
207,232 shs
Market Capitalization
$14.29 billion
P/E Ratio
7.29
Dividend Yield
2.55%
Price Target
$47.58

Fresenius SE & Co. KGaA MarketRank™ Forecast

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
649.9% Upside
$47.58 Price Target
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.47mentions of Fresenius SE & Co. KGaA in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
14.89%
From $0.94 to $1.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.99 out of 5 stars

FSNUY stock logo

About Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Stock

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Receive FSNUY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fresenius SE & Co. KGaA and its competitors with MarketBeat's FREE daily newsletter.

FSNUY Stock News Headlines

Fresenius Medical Care earnings: here's what to expect
Fresenius: Revisiting The Thesis - Still A Buy
Fresenius: Q1 Earnings Snapshot
Fresenius: Undervalued Healthcare Giant
See More Headlines
Receive FSNUY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fresenius SE & Co. KGaA and its competitors with MarketBeat's FREE daily newsletter.

FSNUY Company Calendar

Last Earnings
5/06/2021
Today
8/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:FSNUY
CIK
N/A
Fax
N/A
Employees
316,078
Year Founded
1912

Price Target and Rating

Average Stock Price Forecast
$47.58
High Stock Price Forecast
$87.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+649.9%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

Net Income
$2.15 billion
Pretax Margin
9.35%

Debt

Sales & Book Value

Annual Sales
$44.39 billion
Cash Flow
$2.40 per share
Book Value
$15.51 per share

Miscellaneous

Outstanding Shares
2,252,950,000
Free Float
N/A
Market Cap
$14.29 billion
Optionable
Not Optionable
Beta
1.11

Social Links


Key Executives

  • Mr. Stephan Sturm (Age 59)
    CEO, Pres & Chairman of Management Board - Fresenius Management SE
    Comp: $3.99M
  • Ms. Rachel Clare Empey (Age 46)
    CFO & Member of Management Board - Fresenius Management SE
    Comp: $2.24M
  • Dr. Francesco De Meo (Age 59)
    Member of Management Board - Fresenius Management SE
    Comp: $2.46M
  • Dr. Ernst Wastler (Age 64)
    Member of Management Board - Fresenius Management SE
    Comp: $1.88M
  • Mr. Rice Powell (Age 67)
    Member of Management Board - Fresenius Management SE
    Comp: $4M
  • Dr. Sebastian Biedenkopf (Age 58)
    Chief Legal Officer, HR, Labor Relations Director, Risk Mgmt & Member of Mgmt. Board
    Comp: $1.58M
  • Mr. Michael Sen (Age 54)
    Member of Management Board - Fresenius Management SE
    Comp: $2.34M
  • Mr. Markus Georgi
    Sr. VP of Investor Relations
  • Matthias Link
    Sr. VP Corp. Communications













FSNUY Stock - Frequently Asked Questions

Should I buy or sell Fresenius SE & Co. KGaA stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fresenius SE & Co. KGaA in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FSNUY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FSNUY, but not buy additional shares or sell existing shares.
View FSNUY analyst ratings
or view top-rated stocks.

What is Fresenius SE & Co. KGaA's stock price forecast for 2022?

9 equities research analysts have issued 12-month price targets for Fresenius SE & Co. KGaA's shares. Their FSNUY share price forecasts range from $26.00 to $87.00. On average, they anticipate the company's stock price to reach $47.58 in the next year. This suggests a possible upside of 649.9% from the stock's current price.
View analysts price targets for FSNUY
or view top-rated stocks among Wall Street analysts.

How have FSNUY shares performed in 2022?

Fresenius SE & Co. KGaA's stock was trading at $9.98 at the start of the year. Since then, FSNUY stock has decreased by 36.4% and is now trading at $6.3450.
View the best growth stocks for 2022 here
.

Are investors shorting Fresenius SE & Co. KGaA?

Fresenius SE & Co. KGaA saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 67,700 shares, an increase of 8.3% from the July 15th total of 62,500 shares. Based on an average daily trading volume, of 369,600 shares, the days-to-cover ratio is presently 0.2 days.
View Fresenius SE & Co. KGaA's Short Interest
.

How were Fresenius SE & Co. KGaA's earnings last quarter?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) announced its quarterly earnings results on Thursday, May, 6th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.01. The firm had revenue of $10.83 billion for the quarter. Fresenius SE & Co. KGaA had a trailing twelve-month return on equity of 6.18% and a net margin of 4.39%.

Is Fresenius SE & Co. KGaA a good dividend stock?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) pays an annual dividend of $0.16 per share and currently has a dividend yield of 2.55%. The dividend payout ratio is 18.39%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, FSNUY will have a dividend payout ratio of 14.81% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for FSNUY.

What is Fresenius SE & Co. KGaA's stock symbol?

Fresenius SE & Co. KGaA trades on the OTCMKTS under the ticker symbol "FSNUY."

How do I buy shares of Fresenius SE & Co. KGaA?

Shares of FSNUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fresenius SE & Co. KGaA's stock price today?

One share of FSNUY stock can currently be purchased for approximately $6.35.

How much money does Fresenius SE & Co. KGaA make?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) has a market capitalization of $14.29 billion and generates $44.39 billion in revenue each year. The company earns $2.15 billion in net income (profit) each year or $0.87 on an earnings per share basis.

How many employees does Fresenius SE & Co. KGaA have?

The company employs 316,078 workers across the globe.

When was Fresenius SE & Co. KGaA founded?

Fresenius SE & Co. KGaA was founded in 1912.

How can I contact Fresenius SE & Co. KGaA?

Fresenius SE & Co. KGaA's mailing address is Else-Kroner-Strasse 1, Bad Homburg 2M, 61352. The official website for the company is www.fresenius.com. The company can be reached via phone at (496) 172-6080 or via email at ir-fre@fresenius.com.

This page (OTCMKTS:FSNUY) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.